| Full text | |
| Author(s): |
de Farias, C. R.
[1, 2]
;
Cardoso, B. R.
[3]
;
de Oliveira, G. M. B.
[4]
;
de Mello Guazzelli, I. C.
[5]
;
Catarino, R. M.
[6]
;
Chammas, M. C.
[7]
;
Cozzolino, S. M. F.
[3]
;
Knobel, M.
[1, 2]
Total Authors: 8
|
| Affiliation: | [1] Univ Sao Paulo, Sch Med, Hosp Clin, Thyroid Unit, Div Endocrinol & Metab, PAMB, BR-05403900 Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Sch Med, Hosp Clin, PAMB, Lab Cellular & Mol Biol LIM 25, Div Endocrinol & M, BR-05403900 Sao Paulo, SP - Brazil
[3] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Food & Expt Nutr, BR-05508000 Sao Paulo, SP - Brazil
[4] Univ Sao Paulo, Sch Med, Hosp Clin, Ultrasound Unit, Dept Radiol, BR-05403900 Sao Paulo, SP - Brazil
[5] Univ Sao Paulo, Sch Med, Div Endocrinol & Metab, Lab Cellular & Mol Endocrinol, LIM 25, BR-01246903 Sao Paulo, SP - Brazil
[6] Adolpho Lutz Inst, Ctr Pathol, Hematol & Biochem, BR-01246000 Sao Paulo, SP - Brazil
[7] Univ Sao Paulo, Sch Med, Hosp Clin, Ultrasound Unit, Dept Radiol, BR-05403010 Sao Paulo, SP - Brazil
Total Affiliations: 7
|
| Document type: | Journal article |
| Source: | Journal of Endocrinological Investigation; v. 38, n. 10, p. 1065-1074, OCT 2015. |
| Web of Science Citations: | 23 |
| Abstract | |
Purpose To analyze the impact of selenium supplementation on serum antiTPO levels and thyroid echogenicity in patients with CAT, evaluating the response in subgroups with different GPx1 genotypes. Methods CAT patients (n = 55) with positive antiTPO were randomized to selenomethionine (SeMet) 200 mu g daily (n = 28) or placebo (n = 27) for 3 months. Assessments included GPx1 genotyping at baseline and serum levels of plasma selenium, erythrocyte GPx1 activity, antiTPO and thyroid echogenicity at baseline, and 3 and 6 months. Results In the SeMet group, the increase in plasma levels of selenium and erythrocyte GPx1 activity was similar among patients with different GPx1 genotypes. In the overall cohort, patients randomized to SeMet showed a 5 % decrease in antiTPO levels at 3 months (p = non-significant) and 20 % at 6 months ( p < 0.001 versus 3 months). In contrast, patients in the placebo group did not show significant changes in antiTPO levels at any time point. Subgroup analysis showed that patients with different GPx1 genotypes presented comparable responses in antiTPO levels and echogenicity index to SeMet. Conclusions Selenium supplementation decreased serum antiTPO levels in CAT patients, with similar response among patients with different GPx1 genotypes. (AU) | |